EUVIMEDEUVIMED entdecken
Open Access

Assessing cancer therapeutic efficacy in vivo using [ 2 H 7 ]glucose deuterium metabolic imaging

Mario C Chang iD, Vinay R Malut, Rohit Mahar iD, Anna Rushin iD, Marc A McLeod, Geraldine L Pierre iD, Indu R Malut, Stephen J Staklinski iD, Max E Glanz iD, Mukundan Ragavan iD, Gaurav Sharma iD, Manoj Madheswaran iD und 9 weitere

Science Advances · 2025

DOI: 10.1126/sciadv.adr0568 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, 2025. Verfasst von Mario C Chang und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, University of Florida College of Medicine, Gainesville, FL 32610, USA. Hauptthemen laut MEDLINE: Glucose, Deuterium, Magnetic Resonance Imaging, Neoplasms. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIBIB NIH HHS, NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic imaging produces powerful visual assessments of organ function in vivo. Current techniques can be improved by safely increasing metabolic contrast. The gold standard, 2-[ 18 F]fluorodeoxyglucose-positron emission tomography (FDG-PET) imaging, is limited by radioactive exposure and sparse assessment of metabolism beyond glucose uptake and retention. Deuterium magnetic resonance imaging (DMRI) with [6,6- 2 H 2 ]glucose is nonradioactive, achieves tumor metabolic contrast, but can be improved by enriched contrast from deuterated water (HDO) based imaging. Here, we developed a DMRI protocol employing [ 2 H 7 ]glucose. Imaging 2 H-signal and measuring HDO production in tumor-bearing mice detected differential glucose utilization across baseline tumors, tumors treated with vehicle control or anti-glycolytic BRAFi and MEKi therapy, and contralateral healthy tissue. Control tumors generated the most 2 H-signal and HDO. To our knowledge this is the first application of DMRI with [ 2 H 7 ]glucose for tumoral treatment monitoring. This approach demonstrates HDO as a marker of tumor glucose utilization and suggests translational capability in humans due to its safety, noninvasiveness, and suitability for serial monitoring.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlucoseDeuteriumMagnetic Resonance ImagingNeoplasmsAnimalsMiceHumansCell Line, TumorPositron-Emission TomographyFemaleXenograft Model Antitumor Assays

Substanzen

GlucoseDeuterium

Autor:innen und Institutionen

  • Department of Biochemistry and Molecular Biology, University of Florida College of Medicine, Gainesville, FL 32610, USA.
  • Department of Chemistry, Hemvati Nandan Bahuguna Garhwal University (A Central University), Srinagar Garhwal, Uttarakhand 246174, India.
  • Center for Human Nutrition, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
  • School of Biological Sciences, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA.
  • Department of Structural Biology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
  • Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia.

ORCID-Profile: Mario C Chang, Rohit Mahar, Anna Rushin, Geraldine L Pierre, Stephen J Staklinski, Max E Glanz, Mukundan Ragavan, Gaurav Sharma, Manoj Madheswaran, Arshee Badar, Aparna D Rao, Brian K Law, James H P Collins, Vikram D Kodibagkar, James A Bankson, Ralph J DeBerardinis, Matthew E Merritt

Förderung

  • NIBIB NIH HHS
  • NIDDK NIH HHS

Zitieren

APA

Chang, M. C., Malut, V. R., Mahar, R., Rushin, A., McLeod, M. A., Pierre, G. L., Malut, I. R., Staklinski, S. J., Glanz, M. E., Ragavan, M., Sharma, G., Madheswaran, M., Badar, A., Rao, A. D., Law, B. K., Kilberg, M. S., Collins, J. H. P., Kodibagkar, V. D., Bankson, J. A., …, & Merritt, M. E. (2025). Assessing cancer therapeutic efficacy in vivo using [ 2 H 7 ]glucose deuterium metabolic imaging. Science Advances. https://doi.org/10.1126/sciadv.adr0568

Vancouver

Chang MC, Malut VR, Mahar R, Rushin A, McLeod MA, Pierre GL, et al. Assessing cancer therapeutic efficacy in vivo using [ 2 H 7 ]glucose deuterium metabolic imaging. Science Advances. 2025. doi:10.1126/sciadv.adr0568

BibTeX
@article{Chang2025,
  author = {Chang, Mario C and Malut, Vinay R and Mahar, Rohit and Rushin, Anna and McLeod, Marc A and Pierre, Geraldine L and Malut, Indu R and Staklinski, Stephen J and Glanz, Max E and Ragavan, Mukundan and Sharma, Gaurav and Madheswaran, Manoj and Badar, Arshee and Rao, Aparna D and Law, Brian K and Kilberg, Michael S and Collins, James H P and Kodibagkar, Vikram D and Bankson, James A and DeBerardinis, Ralph J and Merritt, Matthew E},
  title = {Assessing cancer therapeutic efficacy in vivo using [ 2 H 7 ]glucose deuterium metabolic imaging},
  journal = {Science Advances},
  year = {2025},
  doi = {10.1126/sciadv.adr0568}
}
Kostenlos starten →